Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: Case report and review of literature

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 4, 2009, Pages 388-391

  Lo, Yi Chun ^a   Chang, Sui Yuan ^a   Sheng, Wang Huei ^a   Hung, Chien Ching ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Hepatitis C virus; HIV; Human leukocyte antigen haplotypes; Keywords; Pancreatic autoantibody; Pegylated interferon

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; LEUKOCYTE ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; ROBATROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; HAPLOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MALE; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 2; HAPLOTYPES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HLA-D ANTIGENS; HUMANS; INTERFERON ALFA-2A; MALE; PANCREAS; POLYETHYLENE GLYCOLS; REMISSION, SPONTANEOUS;

EID: 67649629041     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328317f4c8     Document Type: Article

References (41)

1. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11舁241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24:38-47.
2. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291.
3. Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008; 28:39-46.
4. Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002; 47:1649-1654.
5. Jabr FI, Ordinario MMD. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 2003; 115:158-159.
6. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23:1177-1181.
7. Koivisto VA, Peklonen R, Cantel K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38:641-647.
8. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340:548.
9. Fabris P, Floreani A, Tositti G, Vergani D, de Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18:549-558.
10. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-229.
11. Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, et al. Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B. Lancet 1994; 343:244.
12. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1996; 125:521.
13. Tsai TN, Hsieh CH. Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection. N Z Med J 2004; 117:U1230.
14. Cozzolongo R, Betterle C, Fabris P, Paola AM, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18:689-692.
15. Tosone G, Borgia G, Gentile I, Cerini R, Conte MC, Orlando R, et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?. Acta Diabetol 2007; 44:167-169.
16. Shiba T, Higashi N, Nishimura Y. Hyperglycaemia due to insulin resistance caused by interferon-gamma. Diabet Med 1998; 15:435-436.
17. Rostaing L, Oksman F, Izopet J, Baron E, Cisterne JM, Hoff M, et al. Serological markers of autoimmunity in renal transplant patients before and after alpha-interferon therapy for chronic hepatitis C. Am J Nephrol 1996; 16:478-483.
18. Gori A, Caredda F, Franzetti F, Ridolfo A, Rusconi S, Moroni M. Reversible diabetes in patient with AIDS-related Kaposi’s sarcoma treated with interferon alpha-2a. Lancet 1995; 345:1438-1439.
19. Frankart L, Lejeune D, Donckier J. Diabetes mellitus and interferon therapy. Diabet Med 1997; 14:405.
20. Whitehead RP, Hauschild A, Christophers E, Figlin R. Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon. Cancer Biother 1995; 10:45-51.
21. Radhakrishnan S, Upadhyay A, Mohan N, Dhar A, Walia HK, Zubaidi G. Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report. Med Princ Pract 2005; 14:281-283.
22. Recasens M, Aguilera E, Ampurdanes S, Sánchez Tapias JM, Simó O, Casamitjana R, et al. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 2001; 18:764-767.
23. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?. Diabet Med 2001; 18:329-332.
24. Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001; 13:295-298.
25. Bhatti A, McGarrity TJ, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Am J Gastroenterol 2001; 96:604-605.
26. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 2003; 56:238-239.
27. Uto H, Matsuoka H, Murata M, Okamoto T, Miyata Y, Hori T, et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 2000; 49:101-106.
28. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28:514-517.
29. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract 1995; 30:237-241.
30. Murakami M, Iriuchijima T, Mori M. Diabetes mellitus and interferon-alpha therapy. Ann Intern Med 1995; 123:318.
31. Guerci AP, Guerci B, Levy-Marchal C, Ongagna J, Ziegler O, Candiloros H, et al. Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia. Lancet 1994; 343:1167-1168.
32. Waguri M, Hanafusa T, Itoh N, Imagawa A, Miyagawa J, Kawata S, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23:33-36.
33. Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 1998; 21:1774.
34. Brar I, Shuter J, Thomas A, Daniels E, Absalon J, Women’s Task Force of Terry Beirn Community Programs for Clinical Research on AIDS. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naïve individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45:66-71.
35. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
36. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
37. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss Cohort Study. Clin Infect Dis 2007; 45:111-119.
38. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003; 125:1695-1704.
39. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38:50-56.
40. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840-848.
41. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Andrade RJ, Diago M, Alonso S, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48:721-727.